Non Small Cell Lung Cancer - Immunotherapy - KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression

Association details:

Biomarker:	KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression
Cancer:	Non Small Cell Lung Cancer
Drug Class:	Immunotherapy
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

Cancers (Basel)

Title:

Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

Published date:

06/06/2022

Excerpt:

NSCLC patients with KMT2C/BCOR/KDM5C mutations had comparable clinical outcomes to TMB-high patients in terms of objective response rate, durable clinical benefit and overall survival...the association of this mutation with better ICB response was independent of tumor TMB and programmed death-ligand 1 (PD-L1) level, and combination of KMT2C/BCOR/KDM5C mutations with TMB or PD-L1 further improve the prediction of ICB response in NSCLC patients...our data indicate that KMT2C/BCOR/KDM5C mutation has the potential to serve as a predictive biomarker, alone or combined with PD-L1 expression or TMB, for ICB therapy in NSCLC.

DOI:

10.3390/cancers14112816